ARTICLE | Top Story
AZ acquires Probiodrug's CDK9 inhibitor program
January 4, 2014 12:53 AM UTC
AstraZeneca plc (LSE:AZN; NYSE:AZN) acquired a cyclin dependent kinase 9 (CDK9) inhibitor program from Probiodrug AG (Halle/Saale, Germany) for undisclosed financial terms. The program includes a lead...